Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies: collective experience in 32 infants.

ABSTRACT: The objective of this retrospective study of patients evaluated between July 2008 and October 2011 in seven pediatric dermatology centers was to combine collective clinical experience using oral propranolol therapy in 32 infants with PHACE syndrome (Posterior fossa [brain malformations present at birth], Hemangioma [usually covering a large area of the skin of the head or neck >5 cm]; Arterial lesions [abnormalities of the blood vessels in the neck or head]; Cardiac abnormalities or aortic coarctation [abnormalities of the heart or blood vessels that are attached to the heart]; Eye abnormalities) with cervical or intracranial arterial anomalies. Patients were given an average daily dose of oral propranolol of 1.8 mg/kg divided two or three times per day for an average duration of 12.3 mont

SUBMITTER: Metry D 

PROVIDER: S-EPMC4995066 | biostudies-literature | 2013 Jan-Feb

REPOSITORIES: biostudies-literature